DEVELOP MULTIPLE SCLEROSIS TREATMENT USING PHAGE DISPLAY

Information

  • Research Project
  • 2793067
  • ApplicationId
    2793067
  • Core Project Number
    R43NS037627
  • Full Project Number
    1R43NS037627-01A1
  • Serial Number
    37627
  • FOA Number
  • Sub Project Id
  • Project Start Date
    8/1/1999 - 25 years ago
  • Project End Date
    1/31/2000 - 25 years ago
  • Program Officer Name
    KERZA-KWIATECKI, A P
  • Budget Start Date
    8/1/1999 - 25 years ago
  • Budget End Date
    1/31/2000 - 25 years ago
  • Fiscal Year
    1999
  • Support Year
    1
  • Suffix
    A1
  • Award Notice Date
    7/16/1999 - 25 years ago
Organizations

DEVELOP MULTIPLE SCLEROSIS TREATMENT USING PHAGE DISPLAY

DESCRIPTION: (Applicant's abstract) Multiple sclerosis (MS) is caused by an autoimmune response against central nervous system (CNS) antigens, resulting in demyelinization of CNS neurons. The matrix metalloproteinase gelatinase B (MMP-9) is produced by T cells and allows transsendothelial migration of activated T cells and antibodies across the blood-brain barrier. Migration of T cells across a basal lamina equivalent in vitro is inhibited by a non-specific MMP inhibitor. Current MS therapies include beta-interferon, which has been shown to reduce the ability of T cells to cross the blood-brain barrier by suppressing MMP-9 production. A specific inhibitor of MMP-9 should therefore have efficacy in prevention or modification of MS attacks without the side effects caused by non-specific activities of current therapies. We propose to use the powerful combinatorial technique of phage display to isolate optimal substrate peptides and high affinity peptides that bind to an inhibit MMP-9. We will construct phage display libraries using information about the structure of MMP-o and its substrates, and will screen these libraries to identify ligands with the desired binding and inhibitory characteristics. In future experiments, the molecules that are isolated will be tested in an established primate model of MS, and then will be developed for clinical evaluation in patients. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

IC Name
NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
  • Activity
    R43
  • Administering IC
    NS
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    853
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
  • Organization Name
    DYAX CORPORATION
  • Organization Department
  • Organization DUNS
  • Organization City
    CAMBRIDGE
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    02139
  • Organization District
    UNITED STATES